For example, in the case of aberrant ALK-expressing non-small cell lung cancer (NSCLC), resistance has been reported in the context of mutations of the target protein that render it insensitive to ALK TKIs and/or amplification leading to an excess of target2–4. This evidence concerns the gene ALK and non-small cell lung carcinoma.